Trial Outcomes & Findings for A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (NCT NCT02484690)

NCT ID: NCT02484690

Last Updated: 2020-11-12

Results Overview

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 273 participants
• Primary outcome timeframe: Baseline, Week 36
• Results posted on: 2020-11-12

Participant Flow

A total of 273 patients were randomized, but 10 participants in total were excluded from the analysis populations, 1, 3, 1, and 5 from Arms B, C, D, and E, respectively, because of Good Clinical Practice (GCP) violations at a single site.

Participant milestones

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Overall Study STARTED	68	46	39	46	64
Overall Study Received at Least One Dose of Study Drug	67	46	39	46	64
Overall Study COMPLETED	64	40	36	44	58
Overall Study NOT COMPLETED	4	6	3	2	6

Reasons for withdrawal

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Overall Study Adverse Event	1	3	0	0	5
Overall Study Death	0	0	0	0	1
Overall Study Withdrawal by Subject	1	3	1	2	0
Overall Study Physician Decision	2	0	1	0	0
Overall Study Lost to Follow-up	0	0	1	0	0

Baseline Characteristics

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Baseline characteristics by cohort

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.	Total n=263 Participants Total of all reporting groups
Age, Continuous	76.4 Years STANDARD_DEVIATION 8.9 • n=5 Participants	78.2 Years STANDARD_DEVIATION 8.9 • n=7 Participants	78.0 Years STANDARD_DEVIATION 9.1 • n=5 Participants	80.0 Years STANDARD_DEVIATION 8.0 • n=4 Participants	79.2 Years STANDARD_DEVIATION 8.3 • n=21 Participants	78.3 Years STANDARD_DEVIATION 8.7 • n=8 Participants
Sex: Female, Male Female	39 Participants n=5 Participants	32 Participants n=7 Participants	27 Participants n=5 Participants	34 Participants n=4 Participants	40 Participants n=21 Participants	172 Participants n=8 Participants
Sex: Female, Male Male	29 Participants n=5 Participants	14 Participants n=7 Participants	12 Participants n=5 Participants	12 Participants n=4 Participants	24 Participants n=21 Participants	91 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	4 Participants n=5 Participants	3 Participants n=7 Participants	0 Participants n=5 Participants	4 Participants n=4 Participants	2 Participants n=21 Participants	13 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	64 Participants n=5 Participants	43 Participants n=7 Participants	38 Participants n=5 Participants	42 Participants n=4 Participants	61 Participants n=21 Participants	248 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	2 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Black or African American	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race (NIH/OMB) White	66 Participants n=5 Participants	45 Participants n=7 Participants	39 Participants n=5 Participants	44 Participants n=4 Participants	64 Participants n=21 Participants	258 Participants n=8 Participants
Race (NIH/OMB) More than one race	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=8 Participants
Best-Corrected Visual Acuity (BCVA) Letter Score in the Study Eye at Baseline	55.2 BCVA Letters STANDARD_DEVIATION 12.7 • n=5 Participants	56.7 BCVA Letters STANDARD_DEVIATION 11.1 • n=7 Participants	56.2 BCVA Letters STANDARD_DEVIATION 12.2 • n=5 Participants	56.3 BCVA Letters STANDARD_DEVIATION 11.5 • n=4 Participants	55.7 BCVA Letters STANDARD_DEVIATION 11.6 • n=21 Participants	55.9 BCVA Letters STANDARD_DEVIATION 11.9 • n=8 Participants
Best-Corrected Visual Acuity (BCVA) Letter Score Category in the Study Eye at Baseline BCVA Letter Score ≤54	22 Participants n=5 Participants	20 Participants n=7 Participants	15 Participants n=5 Participants	21 Participants n=4 Participants	26 Participants n=21 Participants	104 Participants n=8 Participants
Best-Corrected Visual Acuity (BCVA) Letter Score Category in the Study Eye at Baseline BCVA Letter Score >54	45 Participants n=5 Participants	26 Participants n=7 Participants	24 Participants n=5 Participants	25 Participants n=4 Participants	38 Participants n=21 Participants	158 Participants n=8 Participants
Best-Corrected Visual Acuity (BCVA) Letter Score Category in the Study Eye at Baseline Assessment Missing	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline Classic & Occult CNV	26 Participants n=5 Participants	19 Participants n=7 Participants	12 Participants n=5 Participants	20 Participants n=4 Participants	21 Participants n=21 Participants	98 Participants n=8 Participants
Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline Classic CNV	8 Participants n=5 Participants	6 Participants n=7 Participants	7 Participants n=5 Participants	6 Participants n=4 Participants	10 Participants n=21 Participants	37 Participants n=8 Participants
Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline Occult CNV	33 Participants n=5 Participants	20 Participants n=7 Participants	20 Participants n=5 Participants	19 Participants n=4 Participants	33 Participants n=21 Participants	125 Participants n=8 Participants
Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline Assessment Missing	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	3 Participants n=8 Participants
Presence or Absence of Retinal Angiomatous Proliferation (RAP) in the Study Eye at Baseline RAP Absent	44 Participants n=5 Participants	30 Participants n=7 Participants	29 Participants n=5 Participants	29 Participants n=4 Participants	47 Participants n=21 Participants	179 Participants n=8 Participants
Presence or Absence of Retinal Angiomatous Proliferation (RAP) in the Study Eye at Baseline RAP Present	22 Participants n=5 Participants	14 Participants n=7 Participants	9 Participants n=5 Participants	14 Participants n=4 Participants	16 Participants n=21 Participants	75 Participants n=8 Participants
Presence or Absence of Retinal Angiomatous Proliferation (RAP) in the Study Eye at Baseline Assessment Missing	2 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	3 Participants n=4 Participants	1 Participants n=21 Participants	9 Participants n=8 Participants
Presence or Absence of Polypoidal Choroidal Vasculopathy (PCV) in the Study Eye at Baseline PCV Absent	61 Participants n=5 Participants	42 Participants n=7 Participants	36 Participants n=5 Participants	40 Participants n=4 Participants	57 Participants n=21 Participants	236 Participants n=8 Participants
Presence or Absence of Polypoidal Choroidal Vasculopathy (PCV) in the Study Eye at Baseline PCV Present	7 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	5 Participants n=4 Participants	7 Participants n=21 Participants	25 Participants n=8 Participants
Presence or Absence of Polypoidal Choroidal Vasculopathy (PCV) in the Study Eye at Baseline Assessment Missing	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=8 Participants

PRIMARY outcome

Timeframe: Baseline, Week 36

Population: Treatment-naive participants randomized to Arms A, B, C, and D.

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants	7.61 BCVA Letters Interval 5.43 to 9.8	9.18 BCVA Letters Interval 6.54 to 11.83	6.02 BCVA Letters Interval 3.24 to 8.8	6.10 BCVA Letters Interval 3.56 to 8.64	—

PRIMARY outcome

Timeframe: Weeks 12 and 36

Population: Anti-VEGF incomplete responders, which consisted of participants randomized to Arms A and E with BCVA ≤68 at Week 12 with at least one letter improvement relative to Baseline.

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=37 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=38 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders	1.72 BCVA Letters Interval -0.69 to 4.13	0.04 BCVA Letters Interval -2.27 to 2.35	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 36

Population: Treatment-naive participants randomized to Arms A, B, C, and D.

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Percentage of Participants Gaining Greater Than or Equal to (≥) 15 Letters From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants	31.0 Percentage of Participants Interval 24.1 to 38.8	36.6 Percentage of Participants Interval 27.6 to 46.7	27.9 Percentage of Participants Interval 19.6 to 38.0	23.7 Percentage of Participants Interval 16.5 to 32.7	—

SECONDARY outcome

Timeframe: Weeks 12 and 36

Population: Anti-VEGF incomplete responders, which consisted of participants randomized to Arms A and E with BCVA ≤68 at Week 12 with at least one letter improvement relative to Baseline. This analysis only included participants with non-missing assessments at Weeks 12 and 36.

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=35 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=37 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Percentage of Participants Gaining ≥15 Letters From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders	5.71 Percentage of Participants Interval 0.69 to 10.74	0.00 Percentage of Participants Interval 0.0 to 0.0	—	—	—

SECONDARY outcome

Timeframe: Week 36

Population: Treatment-naive participants randomized to Arms A, B, C, and D.

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Treatment-Naive Participants	49.5 Percentage of Participants Interval 41.6 to 57.4	49.0 Percentage of Participants Interval 39.2 to 58.8	39.4 Percentage of Participants Interval 29.8 to 49.9	41.8 Percentage of Participants Interval 32.8 to 51.4	—

SECONDARY outcome

Timeframe: Week 36

Population: Anti-VEGF incomplete responders, which consisted of participants randomized to Arms A and E with BCVA ≤68 at Week 12 with at least one letter improvement relative to Baseline. This analysis only included participants with non-missing assessments at Week 36.

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=35 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=37 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Anti-VEGF Incomplete Responders	22.86 Percentage of Participants Interval 13.76 to 31.95	16.22 Percentage of Participants Interval 8.45 to 23.98	—	—	—

SECONDARY outcome

Timeframe: Week 36

Population: Treatment-naive participants randomized to Arms A, B, C, and D.

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Treatment-Naive Participants	7.7 Percentage of Participants Interval 4.4 to 13.2	8.7 Percentage of Participants Interval 4.6 to 16.0	15.8 Percentage of Participants Interval 9.6 to 25.0	8.8 Percentage of Participants Interval 4.7 to 15.9	—

SECONDARY outcome

Timeframe: Week 36

Population: Anti-VEGF incomplete responders, which consisted of participants randomized to Arms A and E with BCVA ≤68 at Week 12 with at least one letter improvement relative to Baseline. This analysis only included participants with non-missing assessments at Week 36.

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=35 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=37 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Anti-VEGF Incomplete Responders	14.29 Percentage of Participants Interval 6.71 to 21.87	13.51 Percentage of Participants Interval 6.31 to 20.72	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 36

Population: Treatment-naive participants randomized to Arms A, B, C, and D.

Foveal center point thickness (FCPT) is defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea. Foveal center point thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Baseline in Foveal Center Point Thickness at Week 36, as Measured by Spectral Domain Optical Coherence Tomography (SD-OCT), in Treatment-Naive Participants	-194.00 micrometres (μm) Interval -207.01 to -181.0	-181.35 micrometres (μm) Interval -196.9 to -165.81	-193.12 micrometres (μm) Interval -209.49 to -176.76	-161.20 micrometres (μm) Interval -176.15 to -146.25	—

SECONDARY outcome

Timeframe: Weeks 12 and 36

Population: Anti-VEGF incomplete responders, which consisted of participants randomized to Arms A and E with BCVA ≤68 at Week 12 with at least one letter improvement relative to Baseline.

Foveal center point thickness (FCPT) is defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea. Foveal center point thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=37 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=38 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Week 12 in Foveal Center Point Thickness at Week 36, as Measured by SD-OCT, in Anti-VEGF Incomplete Responders	-14.5 micrometres (μm) Interval -28.7 to -0.2	-20.8 micrometres (μm) Interval -34.5 to -7.1	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 36

Population: Treatment-naive participants randomized to Arms A, B, C, and D.

Central subfield thickness (CST) is defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. Central subfield thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Baseline in Central Subfield Thickness at Week 36, as Measured by SD-OCT, in Treatment-Naive Participants	-176.18 micrometres (μm) Interval -188.94 to -163.43	-156.73 micrometres (μm) Interval -171.85 to -141.61	-173.40 micrometres (μm) Interval -189.4 to -157.4	-147.66 micrometres (μm) Interval -162.27 to -133.05	—

SECONDARY outcome

Timeframe: Weeks 12 and 36

Population: Anti-VEGF incomplete responders, which consisted of participants randomized to Arms A and E with BCVA ≤68 at Week 12 with at least one letter improvement relative to Baseline.

Central subfield thickness (CST) is defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. Central subfield thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=37 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=38 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Week 12 in Central Subfield Thickness at Week 36, as Measured by SD-OCT in Anti-VEGF Incomplete Responders	-17.00 micrometres (μm) Interval -33.12 to -0.88	-31.42 micrometres (μm) Interval -46.83 to -16.02	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 36

Population: Treatment-naive participants randomized to Arms A, B, C, and D. This analysis only included participants with presence of the individual dry retina measures (cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid) at Baseline and who were reassessed at Week 36.

The presence of cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. Intraretinal fluid was defined as the presence of fluid within the retina. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Cysts: Present at Baseline	52 Participants	29 Participants	29 Participants	38 Participants	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Cysts: Present at Week 36	13 Participants	7 Participants	6 Participants	11 Participants	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Cysts: Absent at Week 36	36 Participants	18 Participants	21 Participants	25 Participants	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Intraretinal Fluid: Present at Baseline	67 Participants	46 Participants	39 Participants	45 Participants	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Intraretinal Fluid: Present at Week 36	46 Participants	27 Participants	28 Participants	34 Participants	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Intraretinal Fluid: Absent at Week 36	18 Participants	13 Participants	9 Participants	9 Participants	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Pigment Epithelial Detachment: Present at Baseline	58 Participants	37 Participants	27 Participants	36 Participants	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Pigment Epithelial Detachment: Present at Week 36	43 Participants	25 Participants	20 Participants	32 Participants	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Pigment Epithelial Detachment: Absent at Week 36	12 Participants	6 Participants	6 Participants	4 Participants	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Subretinal Fluid: Present at Baseline	56 Participants	41 Participants	30 Participants	35 Participants	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Subretinal Fluid: Present at Week 36	11 Participants	18 Participants	3 Participants	8 Participants	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants Subretinal Fluid: Absent at Week 36	42 Participants	18 Participants	26 Participants	25 Participants	—

SECONDARY outcome

Timeframe: Weeks 12 and 36

Population: Anti-VEGF incomplete responders, consisting of participants randomized to Arms A and E with BCVA ≤68 at Week 12 with ≥1 letter increase from Baseline. Analysis only included those with presence of individual dry retina measures (cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid) at Week 12 and reassessed at Week 36.

The presence of cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. Intraretinal fluid was defined as the presence of fluid within the retina. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=37 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=38 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Cysts: Present at Week 12	9 Participants	11 Participants	—	—	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Cysts: Present at Week 36	4 Participants	5 Participants	—	—	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Cysts: Absent at Week 36	5 Participants	6 Participants	—	—	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Intraretinal Fluid: Present at Week 12	28 Participants	36 Participants	—	—	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Intraretinal Fluid: Present at Week 36	19 Participants	28 Participants	—	—	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Intraretinal Fluid: Absent at Week 36	7 Participants	7 Participants	—	—	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Pigment Epithelial Detachment: Present at Week 12	24 Participants	28 Participants	—	—	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Pigment Epithelial Detachment: Present at Week 36	19 Participants	22 Participants	—	—	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Pigment Epithelial Detachment: Absent at Week 36	3 Participants	5 Participants	—	—	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Subretinal Fluid: Present at Week 12	10 Participants	9 Participants	—	—	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Subretinal Fluid: Present at Week 36	3 Participants	2 Participants	—	—	—
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders Subretinal Fluid: Absent at Week 36	5 Participants	6 Participants	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 36

Population: Treatment-naive participants randomized to Arms A, B, C, and D.

The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by Fundus Fluorescein Angiography (FFA), in Treatment-Naive Participants	-3.41 millimetres squared (mm^2) Interval -4.34 to -2.49	-3.81 millimetres squared (mm^2) Interval -4.93 to -2.7	-3.19 millimetres squared (mm^2) Interval -4.29 to -2.08	-3.31 millimetres squared (mm^2) Interval -4.31 to -2.3	—

SECONDARY outcome

Timeframe: Weeks 12 and 36

Population: Anti-VEGF incomplete responders, which consisted of participants randomized to Arms A and E with BCVA ≤68 at Week 12 with at least one letter improvement relative to Baseline. This analysis only included participants with non-missing assessments at Weeks 12 and 36.

The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA).

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=22 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=21 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders	-0.50 millimetres squared (mm^2) Standard Deviation 2.37	-1.37 millimetres squared (mm^2) Standard Deviation 3.72	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 36

Population: Treatment-naive participants randomized to Arms A, B, C, and D.

The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Treatment-Naive Participants	-4.18 millimetres squared (mm^2) Interval -5.09 to -3.27	-5.14 millimetres squared (mm^2) Interval -6.24 to -4.04	-2.96 millimetres squared (mm^2) Interval -4.09 to -1.82	-3.83 millimetres squared (mm^2) Interval -4.84 to -2.82	—

SECONDARY outcome

Timeframe: Weeks 12 and 36

Population: Anti-VEGF incomplete responders, which consisted of participants randomized to Arms A and E with BCVA ≤68 at Week 12 with at least one letter improvement relative to Baseline. This analysis only included participants with non-missing assessments at Weeks 12 and 36.

The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA).

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=22 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=21 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders	-1.87 millimetres squared (mm^2) Standard Deviation 4.05	-1.88 millimetres squared (mm^2) Standard Deviation 3.98	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 36

Population: Treatment-naive participants randomized to Arms A, B, C, and D.

The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Baseline in Total Area of Leakage at Week 36, as Measured by FFA, in Treatment-Naive Participants	-5.15 millimetres squared (mm^2) Interval -6.1 to -4.2	-5.94 millimetres squared (mm^2) Interval -7.1 to -4.77	-3.71 millimetres squared (mm^2) Interval -4.88 to -2.53	-4.66 millimetres squared (mm^2) Interval -5.7 to -3.61	—

SECONDARY outcome

Timeframe: Weeks 12 and 36

Population: Anti-VEGF incomplete responders, which consisted of participants randomized to Arms A and E with BCVA ≤68 at Week 12 with at least one letter improvement relative to Baseline. This analysis only included participants with non-missing assessments at Weeks 12 and 36.

The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA).

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=22 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=21 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Week 12 in Total Area of Leakage at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders	-1.87 millimetres squared (mm^2) Standard Deviation 4.05	-2.00 millimetres squared (mm^2) Standard Deviation 3.98	—	—	—

SECONDARY outcome

Timeframe: From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

Population: Safety Population: all participants who received at least one dose of study treatment

This safety summary reports the number and percentage of participants who experienced at least one adverse event (AE) during the study. AEs are categorized as any AEs, ocular AEs occurring in the study eye or fellow eye, systemic AEs, serious AEs, AEs related to treatment with study drug, AEs leading to discontinuation (withdrawal) of treatment with study drug, and AEs with fatal outcome. The investigator independently assessed the seriousness and severity for each AE. Severity was graded according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Severity and seriousness are not synonymous; regardless of severity, some AEs may have also met seriousness criteria.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Any Adverse Event (AE)	51 Participants	39 Participants	31 Participants	39 Participants	54 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Ocular AE in Either Eye	39 Participants	25 Participants	23 Participants	29 Participants	37 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Ocular AE in the Study Eye	28 Participants	21 Participants	21 Participants	27 Participants	28 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Ocular AE in the Fellow Eye	21 Participants	16 Participants	9 Participants	18 Participants	20 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Serious Ocular AE in the Study Eye	0 Participants	3 Participants	0 Participants	0 Participants	2 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Ocular AE in Study Eye Leading to Withdrawal	0 Participants	1 Participants	0 Participants	0 Participants	4 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Systemic AE	37 Participants	37 Participants	23 Participants	30 Participants	43 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Serious Systemic AE	9 Participants	7 Participants	7 Participants	4 Participants	6 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Systemic AE Leading to Withdrawal	1 Participants	2 Participants	0 Participants	0 Participants	2 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants AE with Fatal Outcome	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Any Serious AE	9 Participants	11 Participants	7 Participants	5 Participants	8 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Any Related Serious AE	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Any Related AE	3 Participants	4 Participants	3 Participants	3 Participants	0 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Related Ocular AE in the Study Eye	3 Participants	4 Participants	3 Participants	3 Participants	0 Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants Related Systemic AE	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

Population: Safety Population: all participants who received at least one dose of study treatment

The investigator assessed adverse event severity according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Only the most severe intensity was counted for multiple occurrences of the same adverse event per participant at the preferred term level. Severity and seriousness are not synonymous; regardless of severity, some adverse events may have also met seriousness criteria.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Number of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants Study Eye - Adverse Event (AE) of Any Grade	28 Participants	21 Participants	21 Participants	27 Participants	28 Participants
Number of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants Study Eye - Mild AE	27 Participants	19 Participants	20 Participants	25 Participants	24 Participants
Number of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants Study Eye - Moderate AE	4 Participants	2 Participants	3 Participants	6 Participants	8 Participants
Number of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants Study Eye - Severe AE	0 Participants	3 Participants	0 Participants	0 Participants	2 Participants
Number of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants Fellow Eye - AE of Any Grade	21 Participants	16 Participants	9 Participants	18 Participants	20 Participants
Number of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants Fellow Eye - Mild AE	15 Participants	14 Participants	7 Participants	17 Participants	17 Participants
Number of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants Fellow Eye - Moderate AE	5 Participants	1 Participants	4 Participants	1 Participants	2 Participants
Number of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants Fellow Eye - Severe AE	1 Participants	1 Participants	0 Participants	0 Participants	2 Participants

SECONDARY outcome

Timeframe: From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

Population: Safety Population: all participants who received at least one dose of study treatment

The investigator assessed adverse event severity according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Only the most severe intensity was counted for multiple occurrences of the same adverse event per participant at the preferred term level. Severity and seriousness are not synonymous; regardless of severity, some adverse events may have also met seriousness criteria.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Number of Participants With at Least One Systemic Adverse Event by Highest Intensity, in All Participants Any Grade	37 Participants	37 Participants	23 Participants	30 Participants	43 Participants
Number of Participants With at Least One Systemic Adverse Event by Highest Intensity, in All Participants Mild	30 Participants	27 Participants	17 Participants	23 Participants	28 Participants
Number of Participants With at Least One Systemic Adverse Event by Highest Intensity, in All Participants Moderate	16 Participants	18 Participants	14 Participants	13 Participants	26 Participants
Number of Participants With at Least One Systemic Adverse Event by Highest Intensity, in All Participants Severe	7 Participants	2 Participants	5 Participants	4 Participants	4 Participants

SECONDARY outcome

Timeframe: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

Population: Safety Population: all participants who received at least one dose of study treatment. In this analysis, the number of participants with an abnormal vital sign (numerator) is reported among the number analyzed (denominator), which represents the number of participants without the abnormal vital sign at baseline.

Abnormal systolic blood pressure (supine) was defined as any value outside of the standard reference range, from <70 (low) to >140 (high) millimetres of mercury (mmHg). Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Number of Participants With Abnormal Systolic Blood Pressure, in All Participants Low	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Systolic Blood Pressure, in All Participants High	20 Participants	13 Participants	13 Participants	23 Participants	25 Participants

SECONDARY outcome

Timeframe: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

Population: Safety Population: all participants who received at least one dose of study treatment. In this analysis, the number of participants with an abnormal vital sign (numerator) is reported among the number analyzed (denominator), which represents the number of participants without the abnormal vital sign at baseline.

Abnormal diastolic blood pressure (supine) was defined as any value outside of the standard reference range, from <40 (low) to >90 (high) millimetres of mercury (mmHg). Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Number of Participants With Abnormal Diastolic Blood Pressure, in All Participants Low	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Diastolic Blood Pressure, in All Participants High	15 Participants	9 Participants	8 Participants	10 Participants	9 Participants

SECONDARY outcome

Timeframe: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

Population: Safety Population: all participants who received at least one dose of study treatment. In this analysis, the number of participants with an abnormal vital sign (numerator) is reported among the number analyzed (denominator), which represents the number of participants without the abnormal vital sign at baseline.

Abnormal heart rate (supine) was defined as any value outside of the standard reference range, from <40 (low) to >100 (high) beats per minute. Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Number of Participants With Abnormal Heart Rate, in All Participants Low	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Heart Rate, in All Participants High	1 Participants	0 Participants	1 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

Population: Safety Population: all participants who received at least one dose of study treatment. In this analysis, the number of participants with an abnormal vital sign (numerator) is reported among the number analyzed (denominator), which represents the number of participants without the abnormal vital sign at baseline.

Abnormal body temperature (supine) was defined as any value outside of the standard reference range, from <36.5 (low) to >37.5 (high) degrees Celsius. Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Number of Participants With Abnormal Body Temperature, in All Participants High	4 Participants	1 Participants	1 Participants	2 Participants	6 Participants
Number of Participants With Abnormal Body Temperature, in All Participants Low	28 Participants	19 Participants	14 Participants	25 Participants	29 Participants

SECONDARY outcome

Timeframe: Predose at Baseline, Weeks 12 and 36, and at Early Termination and Unscheduled Visits (up to 36 weeks)

Population: Safety Population: all participants who received at least one dose of study treatment. This analysis included participants with non-missing assessments.

Clinical laboratory tests for hematology and coagulation parameters were performed and any marked abnormal values (High or Low) were based on Roche's predefined standard reference ranges. Marked laboratory abnormalities are presented according to COG3007 abnormality criteria: Single, Not Last = abnormality detected at a single assessment, but not at the last assessment; Last or Replicated = abnormality detected at the last assessment or replicated at one or more assessments. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Abs. = absolute count; Corp. = corpuscular; Ery. = erythrocyte; INR = International Normalized Ratio

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Hemoglobin, Low - Last or Replicated	1 Participants	0 Participants	1 Participants	2 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Lymphocytes, Abs., Low - Any Abnormality	0 Participants	1 Participants	1 Participants	2 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Basophils, Abs., High - Any Abnormality	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Basophils, Abs., High - Single, Not Last	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Basophils, Abs., High - Last or Replicated	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Eosinophils, Abs., High - Any Abnormality	0 Participants	0 Participants	0 Participants	3 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Eosinophils, Abs., High - Single, Not Last	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Eosinophils, Abs., High - Last or Replicated	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Ery. Mean Corp. Volume, Low - Any Abnormality	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Ery. Mean Corp. Volume, Low - Single, Not Last	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Ery. Mean Corp. Volume, Low - Last or Replicated	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Hematocrit, Low - Any Abnormality	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Hematocrit, Low - Single, Not Last	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Hematocrit, Low - Last or Replicated	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Hemoglobin, Low - Any Abnormality	3 Participants	0 Participants	1 Participants	2 Participants	2 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Hemoglobin, Low - Single, Not Last	2 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Lymphocytes, Abs., Low - Single, Not Last	0 Participants	1 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Lymphocytes, Abs., Low - Last or Replicated	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Lymphocytes, Abs., High - Any Abnormality	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Lymphocytes, Abs., High - Single, Not Last	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Lymphocytes, Abs., High - Last or Replicated	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Lymphocytes, Pct., Low - Any Abnormality	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Lymphocytes, Pct., Low - Single, Not Last	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Lymphocytes, Pct., Low - Last or Replicated	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Neutrophils, Total, Abs., Low - Any Abnormality	0 Participants	1 Participants	2 Participants	3 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Neutrophils, Total, Abs., Low - Single, Not Last	0 Participants	1 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Neutrophils, Total, Abs., Low - Last or Replicated	0 Participants	0 Participants	1 Participants	2 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Neutrophils, Total, Abs., High - Any Abnormality	2 Participants	1 Participants	0 Participants	0 Participants	2 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Neutrophils, Total, Abs., High - Single, Not Last	1 Participants	0 Participants	0 Participants	0 Participants	2 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Neutrophils, Total, Abs., High -Last or Replicated	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Platelets, Low - Any Abnormality	0 Participants	0 Participants	0 Participants	2 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Platelets, Low - Single, Not Last	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants Platelets, Low - Last or Replicated	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants White Blood Cell Count, Low - Any Abnormality	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants White Blood Cell Count, Low - Single, Not Last	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants White Blood Cell Count, Low - Last or Replicated	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants White Blood Cell Count, High - Any Abnormality	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants White Blood Cell Count, High - Single, Not Last	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants White Blood Cell Count, High - Last or Replicated	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants INR, High - Any Abnormality	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants INR, High - Single, Not Last	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants INR, High - Last or Replicated	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants

SECONDARY outcome

Timeframe: Predose at Baseline, Weeks 12 and 36, and at Early Termination and Unscheduled Visits (up to 36 weeks)

Population: Safety Population: all participants who received at least one dose of study treatment. This analysis included participants with non-missing assessments.

Clinical laboratory tests for blood chemistry parameters were performed and any marked abnormal values (High or Low) were based on Roche's predefined standard reference ranges. Marked laboratory abnormalities are presented according to COG3007 abnormality criteria: Single, Not Last = abnormality detected at a single assessment, but not at the last assessment; Last or Replicated = abnormality detected at the last assessment or replicated at one or more assessments. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. GGT = gamma-glutamyltransferase; SGOT/AST = serum glutamic oxaloacetic transaminase / aspartate aminotransferase; SGPT/ALT = serum glutamic pyruvic transaminase / alanine aminotransferase

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Alkaline Phosphatase, High - Any Abnormality	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Alkaline Phosphatase, High - Single, Not Last	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Alkaline Phosphatase, High - Last or Replicated	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Bicarbonate (CO2), Low - Any Abnormality	1 Participants	1 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Bicarbonate (CO2), Low - Single, Not Last	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Bicarbonate (CO2), Low - Last or Replicated	1 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Bicarbonate (CO2), High - Any Abnormality	5 Participants	3 Participants	1 Participants	3 Participants	4 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Bicarbonate (CO2), High - Single, Not Last	3 Participants	0 Participants	1 Participants	0 Participants	2 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Bicarbonate (CO2), High - Last or Replicated	2 Participants	3 Participants	0 Participants	3 Participants	2 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Calcium, Low - Any Abnormality	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Calcium, Low - Single, Not Last	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Calcium, Low - Last or Replicated	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Calcium, High - Any Abnormality	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Calcium, High - Single, Not Last	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Calcium, High - Last or Replicated	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Chloride, Low - Any Abnormality	1 Participants	1 Participants	0 Participants	0 Participants	2 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Chloride, Low - Single, Not Last	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Chloride, Low - Last or Replicated	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Creatine Kinase, High - Any Abnormality	2 Participants	0 Participants	1 Participants	3 Participants	2 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Creatine Kinase, High - Single, Not Last	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Creatine Kinase, High - Last or Replicated	2 Participants	0 Participants	1 Participants	2 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Creatinine, High - Any Abnormality	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Creatinine, High - Single, Not Last	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Creatinine, High - Last or Replicated	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants GGT, High - Any Abnormality	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants GGT, High - Single, Not Last	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants GGT, High - Last or Replicated	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Phosphorus, Low - Any Abnormality	0 Participants	1 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Phosphorus, Low - Single, Not Last	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Phosphorus, Low - Last or Replicated	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Phosphorus, High - Any Abnormality	2 Participants	3 Participants	2 Participants	1 Participants	5 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Phosphorus, High - Single, Not Last	1 Participants	1 Participants	1 Participants	1 Participants	3 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Phosphorus, High - Last or Replicated	1 Participants	2 Participants	1 Participants	0 Participants	2 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Potassium, High - Any Abnormality	2 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Potassium, High - Single, Not Last	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Potassium, High - Last or Replicated	1 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Protein, Total, High - Any Abnormality	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Protein, Total, High - Single, Not Last	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants Protein, Total, High - Last or Replicated	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants SGOT/AST, High - Any Abnormality	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants SGOT/AST, High - Single, Not Last	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants SGOT/AST, High - Last or Replicated	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants SGPT/ALT, High - Any Abnormality	1 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants SGPT/ALT, High - Single, Not Last	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants SGPT/ALT, High - Last or Replicated	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline, 0.5 hours postdose on Day 1, predose and 0.5 hours postdose at Weeks 4, 8, 12, 16, 20, 24, 28, and 32, and at Weeks 1, 13, and 36

Population: Safety Population: all participants who received at least one dose of study treatment

Intraocular pressure is the fluid pressure inside the eye. The method used to measure intraocular pressure (e.g., Goldmann tonometry) for each participant was to be applied consistently by the investigator throughout the study. On the day of dosing, intraocular pressure was monitored at 30 minutes post-treatment administration, and if intraocular pressure was ≥30 mmHg in the study eye, it was reassessed at 1 hour post-treatment administration.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 20 (0.5 hr)	2.80 millimetres of mercury (mmHg) Standard Deviation 4.81	1.74 millimetres of mercury (mmHg) Standard Deviation 4.85	1.82 millimetres of mercury (mmHg) Standard Deviation 5.37	0.68 millimetres of mercury (mmHg) Standard Deviation 5.45	2.62 millimetres of mercury (mmHg) Standard Deviation 4.54
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 24 (Predose)	0.00 millimetres of mercury (mmHg) Standard Deviation 3.29	-0.33 millimetres of mercury (mmHg) Standard Deviation 3.30	0.26 millimetres of mercury (mmHg) Standard Deviation 2.77	-0.61 millimetres of mercury (mmHg) Standard Deviation 2.73	0.14 millimetres of mercury (mmHg) Standard Deviation 2.73
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 24 (0.5 hr)	3.23 millimetres of mercury (mmHg) Standard Deviation 3.91	3.26 millimetres of mercury (mmHg) Standard Deviation 4.04	4.11 millimetres of mercury (mmHg) Standard Deviation 3.51	0.91 millimetres of mercury (mmHg) Standard Deviation 3.66	4.17 millimetres of mercury (mmHg) Standard Deviation 4.28
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 28 (Predose)	-0.02 millimetres of mercury (mmHg) Standard Deviation 2.80	0.00 millimetres of mercury (mmHg) Standard Deviation 4.30	-1.00 millimetres of mercury (mmHg) Standard Deviation 2.91	-0.38 millimetres of mercury (mmHg) Standard Deviation 2.74	-0.19 millimetres of mercury (mmHg) Standard Deviation 2.89
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 28 (0.5 hr)	3.16 millimetres of mercury (mmHg) Standard Deviation 4.28	2.90 millimetres of mercury (mmHg) Standard Deviation 4.13	1.74 millimetres of mercury (mmHg) Standard Deviation 4.80	2.53 millimetres of mercury (mmHg) Standard Deviation 3.60	3.86 millimetres of mercury (mmHg) Standard Deviation 4.49
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 32 (Predose)	-0.73 millimetres of mercury (mmHg) Standard Deviation 3.72	-0.23 millimetres of mercury (mmHg) Standard Deviation 3.63	-0.41 millimetres of mercury (mmHg) Standard Deviation 3.07	-0.80 millimetres of mercury (mmHg) Standard Deviation 2.92	-0.67 millimetres of mercury (mmHg) Standard Deviation 3.06
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 32 (0.5 hr)	1.81 millimetres of mercury (mmHg) Standard Deviation 5.10	3.87 millimetres of mercury (mmHg) Standard Deviation 5.58	1.63 millimetres of mercury (mmHg) Standard Deviation 5.47	-0.98 millimetres of mercury (mmHg) Standard Deviation 4.38	2.37 millimetres of mercury (mmHg) Standard Deviation 4.97
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 36	0.00 millimetres of mercury (mmHg) Standard Deviation 3.30	0.25 millimetres of mercury (mmHg) Standard Deviation 3.68	-0.65 millimetres of mercury (mmHg) Standard Deviation 3.85	-0.20 millimetres of mercury (mmHg) Standard Deviation 3.55	-0.16 millimetres of mercury (mmHg) Standard Deviation 3.18
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 13	-0.77 millimetres of mercury (mmHg) Standard Deviation 3.27	-0.68 millimetres of mercury (mmHg) Standard Deviation 3.12	-0.71 millimetres of mercury (mmHg) Standard Deviation 4.02	-1.09 millimetres of mercury (mmHg) Standard Deviation 2.70	-0.65 millimetres of mercury (mmHg) Standard Deviation 2.75
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 16 (Predose)	-0.41 millimetres of mercury (mmHg) Standard Deviation 3.39	0.02 millimetres of mercury (mmHg) Standard Deviation 3.10	-0.77 millimetres of mercury (mmHg) Standard Deviation 3.11	-1.00 millimetres of mercury (mmHg) Standard Deviation 2.56	-0.36 millimetres of mercury (mmHg) Standard Deviation 2.83
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Baseline (BL): Absolute Value	15.07 millimetres of mercury (mmHg) Standard Deviation 3.38	14.74 millimetres of mercury (mmHg) Standard Deviation 3.08	14.69 millimetres of mercury (mmHg) Standard Deviation 3.85	14.98 millimetres of mercury (mmHg) Standard Deviation 2.91	14.27 millimetres of mercury (mmHg) Standard Deviation 2.80
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Day 1 (0.5 hr)	1.90 millimetres of mercury (mmHg) Standard Deviation 4.80	2.04 millimetres of mercury (mmHg) Standard Deviation 5.32	1.59 millimetres of mercury (mmHg) Standard Deviation 4.30	2.37 millimetres of mercury (mmHg) Standard Deviation 4.22	3.52 millimetres of mercury (mmHg) Standard Deviation 4.79
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 1	-0.89 millimetres of mercury (mmHg) Standard Deviation 3.52	-0.98 millimetres of mercury (mmHg) Standard Deviation 3.47	-0.62 millimetres of mercury (mmHg) Standard Deviation 3.35	-1.96 millimetres of mercury (mmHg) Standard Deviation 2.98	0.11 millimetres of mercury (mmHg) Standard Deviation 2.36
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 4 (Predose)	-0.27 millimetres of mercury (mmHg) Standard Deviation 3.16	-1.40 millimetres of mercury (mmHg) Standard Deviation 2.61	-1.18 millimetres of mercury (mmHg) Standard Deviation 3.85	-0.87 millimetres of mercury (mmHg) Standard Deviation 2.99	0.59 millimetres of mercury (mmHg) Standard Deviation 2.49
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 4 (0.5 hr)	2.88 millimetres of mercury (mmHg) Standard Deviation 4.45	2.70 millimetres of mercury (mmHg) Standard Deviation 3.56	2.05 millimetres of mercury (mmHg) Standard Deviation 4.26	1.51 millimetres of mercury (mmHg) Standard Deviation 3.96	3.59 millimetres of mercury (mmHg) Standard Deviation 4.39
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 8 (Predose)	-0.56 millimetres of mercury (mmHg) Standard Deviation 3.85	-0.32 millimetres of mercury (mmHg) Standard Deviation 3.13	-0.69 millimetres of mercury (mmHg) Standard Deviation 3.07	-0.87 millimetres of mercury (mmHg) Standard Deviation 2.75	0.10 millimetres of mercury (mmHg) Standard Deviation 2.64
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 8 (0.5 hr)	2.70 millimetres of mercury (mmHg) Standard Deviation 4.21	2.59 millimetres of mercury (mmHg) Standard Deviation 4.64	2.37 millimetres of mercury (mmHg) Standard Deviation 5.15	1.93 millimetres of mercury (mmHg) Standard Deviation 3.91	3.93 millimetres of mercury (mmHg) Standard Deviation 4.52
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 12 (Predose)	-0.17 millimetres of mercury (mmHg) Standard Deviation 3.49	-0.02 millimetres of mercury (mmHg) Standard Deviation 2.88	-0.82 millimetres of mercury (mmHg) Standard Deviation 3.37	0.13 millimetres of mercury (mmHg) Standard Deviation 2.94	0.45 millimetres of mercury (mmHg) Standard Deviation 2.45
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 12 (0.5 hr)	3.08 millimetres of mercury (mmHg) Standard Deviation 4.01	2.43 millimetres of mercury (mmHg) Standard Deviation 3.41	2.59 millimetres of mercury (mmHg) Standard Deviation 3.95	2.11 millimetres of mercury (mmHg) Standard Deviation 4.04	4.34 millimetres of mercury (mmHg) Standard Deviation 5.25
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 16 (0.5 hr)	1.64 millimetres of mercury (mmHg) Standard Deviation 4.62	1.95 millimetres of mercury (mmHg) Standard Deviation 5.35	1.67 millimetres of mercury (mmHg) Standard Deviation 3.92	-0.30 millimetres of mercury (mmHg) Standard Deviation 3.98	3.12 millimetres of mercury (mmHg) Standard Deviation 5.27
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants Change from BL at Week 20 (Predose)	-0.16 millimetres of mercury (mmHg) Standard Deviation 3.02	-1.00 millimetres of mercury (mmHg) Standard Deviation 2.73	0.08 millimetres of mercury (mmHg) Standard Deviation 3.61	-0.44 millimetres of mercury (mmHg) Standard Deviation 3.18	-0.17 millimetres of mercury (mmHg) Standard Deviation 2.71

SECONDARY outcome

Timeframe: Baseline, Predose (0 hour) on Days 1, 28, 84, 112, 168, and 252 or early termination (up to 36 weeks)

Population: Safety Population: all participants who received at least one dose of study treatment. The analysis only included participants who received treatment with faricimab (i.e., Arm A was excluded) and had evaluable samples at baseline and any post-baseline timepoint.

Blood samples were obtained for measurement of anti-faricimab antibodies by a validated enzyme-linked immunosorbent assay (ELISA).

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=38 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=63 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Change From Baseline in the Number of Participants With Anti-Drug Antibodies to Faricimab at Any Post-Baseline Timepoint ADA Negative to ADA Positive	—	3 Participants	3 Participants	9 Participants	6 Participants
Change From Baseline in the Number of Participants With Anti-Drug Antibodies to Faricimab at Any Post-Baseline Timepoint ADA Positive to Missing	—	0 Participants	0 Participants	0 Participants	0 Participants
Change From Baseline in the Number of Participants With Anti-Drug Antibodies to Faricimab at Any Post-Baseline Timepoint ADA Positive to ADA Negative	—	1 Participants	0 Participants	0 Participants	0 Participants
Change From Baseline in the Number of Participants With Anti-Drug Antibodies to Faricimab at Any Post-Baseline Timepoint ADA Positive to ADA Positive	—	0 Participants	0 Participants	1 Participants	3 Participants
Change From Baseline in the Number of Participants With Anti-Drug Antibodies to Faricimab at Any Post-Baseline Timepoint ADA Negative to Missing	—	1 Participants	0 Participants	0 Participants	0 Participants
Change From Baseline in the Number of Participants With Anti-Drug Antibodies to Faricimab at Any Post-Baseline Timepoint ADA Negative to ADA Negative	—	41 Participants	35 Participants	36 Participants	54 Participants

SECONDARY outcome

Timeframe: Predose (on days when treatment was administered) at Baseline and Weeks 4, 12, 13, 16, 24, and 36

Population: Analysis included all randomized participants who had received treatment with faricimab (i.e., excludes Arm A at all timepoints and Arm E at Week 4) and had evaluable pharmacokinetic samples at a given timepoint.

Plasma concentrations of faricimab were measured by a specific validated enzyme-linked immunoabsorbent assay (ELISA) only from samples of participants randomized to receive faricimab. Baseline was defined as the last non-missing predose assessment. The lower limit of quantification (LLOQ) for the faricimab assay was 0.800 nanograms per millilitre (ng/mL). Values below the limit of quantification were imputed as LLOQ divided by 2.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Plasma Concentration of Faricimab Over Time, in All Participants Baseline	—	0.40 nanograms per millilitre (ng/mL) Standard Deviation 0.00	0.40 nanograms per millilitre (ng/mL) Standard Deviation 0.00	0.40 nanograms per millilitre (ng/mL) Standard Deviation 0.00	0.47 nanograms per millilitre (ng/mL) Standard Deviation 0.59
Mean Plasma Concentration of Faricimab Over Time, in All Participants Week 4	—	8.83 nanograms per millilitre (ng/mL) Standard Deviation 5.85	31.06 nanograms per millilitre (ng/mL) Standard Deviation 18.47	36.58 nanograms per millilitre (ng/mL) Standard Deviation 19.78	—
Mean Plasma Concentration of Faricimab Over Time, in All Participants Week 12	—	18.68 nanograms per millilitre (ng/mL) Standard Deviation 24.38	57.92 nanograms per millilitre (ng/mL) Standard Deviation 57.65	57.94 nanograms per millilitre (ng/mL) Standard Deviation 73.91	45.29 nanograms per millilitre (ng/mL) Standard Deviation 105.64
Mean Plasma Concentration of Faricimab Over Time, in All Participants Week 13	—	43.32 nanograms per millilitre (ng/mL) Standard Deviation 31.98	184.38 nanograms per millilitre (ng/mL) Standard Deviation 102.01	178.25 nanograms per millilitre (ng/mL) Standard Deviation 119.98	160.52 nanograms per millilitre (ng/mL) Standard Deviation 124.73
Mean Plasma Concentration of Faricimab Over Time, in All Participants Week 16	—	9.52 nanograms per millilitre (ng/mL) Standard Deviation 7.41	46.99 nanograms per millilitre (ng/mL) Standard Deviation 35.19	43.54 nanograms per millilitre (ng/mL) Standard Deviation 39.05	44.71 nanograms per millilitre (ng/mL) Standard Deviation 50.55
Mean Plasma Concentration of Faricimab Over Time, in All Participants Week 24	—	9.07 nanograms per millilitre (ng/mL) Standard Deviation 7.39	35.30 nanograms per millilitre (ng/mL) Standard Deviation 22.03	31.19 nanograms per millilitre (ng/mL) Standard Deviation 24.13	37.80 nanograms per millilitre (ng/mL) Standard Deviation 27.75
Mean Plasma Concentration of Faricimab Over Time, in All Participants Week 36	—	10.65 nanograms per millilitre (ng/mL) Standard Deviation 8.47	36.43 nanograms per millilitre (ng/mL) Standard Deviation 30.80	4.69 nanograms per millilitre (ng/mL) Standard Deviation 7.24	36.06 nanograms per millilitre (ng/mL) Standard Deviation 26.93

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 12, 13, 16, 24, and 36

Population: Analysis included all randomized participants who had received study treatment and had evaluable pharmacodynamic samples at a given timepoint.

The concentration of free VEGF was determined in plasma samples using an enzyme-linked immunosorbent assay (ELISA) method. The lower limit of quantification (LLOQ) of the assay was 15.6 picograms per millilitre (pg/mL). Plasma free VEGF concentrations below the limit of quantification were imputed as LLOQ divided by 2.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Baseline in Free Vascular Endothelial Growth Factor-A (VEGF-A) Plasma Concentrations Over Time, in All Participants Baseline (BL) - Value at Visit	15.25 picograms per millilitre (pg/mL) Standard Deviation 10.60	16.83 picograms per millilitre (pg/mL) Standard Deviation 12.08	24.63 picograms per millilitre (pg/mL) Standard Deviation 31.47	16.53 picograms per millilitre (pg/mL) Standard Deviation 9.73	22.60 picograms per millilitre (pg/mL) Standard Deviation 27.79
Mean Change From Baseline in Free Vascular Endothelial Growth Factor-A (VEGF-A) Plasma Concentrations Over Time, in All Participants Change from BL at Week 4	0.52 picograms per millilitre (pg/mL) Standard Deviation 12.20	3.94 picograms per millilitre (pg/mL) Standard Deviation 33.25	-9.26 picograms per millilitre (pg/mL) Standard Deviation 27.76	-0.62 picograms per millilitre (pg/mL) Standard Deviation 15.67	3.75 picograms per millilitre (pg/mL) Standard Deviation 53.99
Mean Change From Baseline in Free Vascular Endothelial Growth Factor-A (VEGF-A) Plasma Concentrations Over Time, in All Participants Change from BL at Week 12	1.52 picograms per millilitre (pg/mL) Standard Deviation 19.45	-0.46 picograms per millilitre (pg/mL) Standard Deviation 13.30	-8.58 picograms per millilitre (pg/mL) Standard Deviation 20.73	-4.70 picograms per millilitre (pg/mL) Standard Deviation 11.79	-3.24 picograms per millilitre (pg/mL) Standard Deviation 27.79
Mean Change From Baseline in Free Vascular Endothelial Growth Factor-A (VEGF-A) Plasma Concentrations Over Time, in All Participants Change from BL at Week 13	2.62 picograms per millilitre (pg/mL) Standard Deviation 21.69	5.47 picograms per millilitre (pg/mL) Standard Deviation 52.19	-14.10 picograms per millilitre (pg/mL) Standard Deviation 33.55	-7.36 picograms per millilitre (pg/mL) Standard Deviation 10.67	-15.14 picograms per millilitre (pg/mL) Standard Deviation 33.85
Mean Change From Baseline in Free Vascular Endothelial Growth Factor-A (VEGF-A) Plasma Concentrations Over Time, in All Participants Change from BL at Week 16	12.12 picograms per millilitre (pg/mL) Standard Deviation 67.43	-3.28 picograms per millilitre (pg/mL) Standard Deviation 10.61	-9.86 picograms per millilitre (pg/mL) Standard Deviation 33.05	-6.28 picograms per millilitre (pg/mL) Standard Deviation 10.84	-5.34 picograms per millilitre (pg/mL) Standard Deviation 32.90
Mean Change From Baseline in Free Vascular Endothelial Growth Factor-A (VEGF-A) Plasma Concentrations Over Time, in All Participants Change from BL at Week 24	-0.67 picograms per millilitre (pg/mL) Standard Deviation 10.45	10.35 picograms per millilitre (pg/mL) Standard Deviation 50.09	-12.57 picograms per millilitre (pg/mL) Standard Deviation 31.86	-5.20 picograms per millilitre (pg/mL) Standard Deviation 10.07	-7.19 picograms per millilitre (pg/mL) Standard Deviation 31.54
Mean Change From Baseline in Free Vascular Endothelial Growth Factor-A (VEGF-A) Plasma Concentrations Over Time, in All Participants Change from BL at Week 36	1.91 picograms per millilitre (pg/mL) Standard Deviation 28.59	-0.79 picograms per millilitre (pg/mL) Standard Deviation 11.86	-12.16 picograms per millilitre (pg/mL) Standard Deviation 32.48	-1.34 picograms per millilitre (pg/mL) Standard Deviation 13.69	-8.17 picograms per millilitre (pg/mL) Standard Deviation 29.73

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 12, 13, 16, 24, and 36

Population: Analysis included all randomized participants who had received study treatment and had evaluable pharmacodynamic samples at a given timepoint.

Total Ang-2 concentrations were determined in plasma samples using an appropriate assay method. The lower limit of quantification (LLOQ) of the assay was 0.09 nanograms per millilitre (ng/mL). Plasma total Ang-2 concentrations below the limit of quantification were imputed as LLOQ divided by 2.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Baseline in Total Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Baseline (BL) - Value at Visit	2.14 nanograms per millilitre (ng/mL) Standard Deviation 1.38	1.81 nanograms per millilitre (ng/mL) Standard Deviation 0.67	1.86 nanograms per millilitre (ng/mL) Standard Deviation 1.12	1.80 nanograms per millilitre (ng/mL) Standard Deviation 0.71	1.92 nanograms per millilitre (ng/mL) Standard Deviation 0.95
Mean Change From Baseline in Total Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 4	0.03 nanograms per millilitre (ng/mL) Standard Deviation 0.48	0.09 nanograms per millilitre (ng/mL) Standard Deviation 0.39	0.09 nanograms per millilitre (ng/mL) Standard Deviation 0.27	0.20 nanograms per millilitre (ng/mL) Standard Deviation 0.49	-0.03 nanograms per millilitre (ng/mL) Standard Deviation 0.38
Mean Change From Baseline in Total Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 12	0.10 nanograms per millilitre (ng/mL) Standard Deviation 0.89	0.14 nanograms per millilitre (ng/mL) Standard Deviation 0.37	0.22 nanograms per millilitre (ng/mL) Standard Deviation 0.48	0.19 nanograms per millilitre (ng/mL) Standard Deviation 0.50	-0.11 nanograms per millilitre (ng/mL) Standard Deviation 0.49
Mean Change From Baseline in Total Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 13	0.18 nanograms per millilitre (ng/mL) Standard Deviation 0.91	0.23 nanograms per millilitre (ng/mL) Standard Deviation 0.35	1.05 nanograms per millilitre (ng/mL) Standard Deviation 1.15	0.87 nanograms per millilitre (ng/mL) Standard Deviation 0.76	0.81 nanograms per millilitre (ng/mL) Standard Deviation 0.98
Mean Change From Baseline in Total Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 16	0.01 nanograms per millilitre (ng/mL) Standard Deviation 0.62	0.04 nanograms per millilitre (ng/mL) Standard Deviation 0.71	0.24 nanograms per millilitre (ng/mL) Standard Deviation 0.47	0.22 nanograms per millilitre (ng/mL) Standard Deviation 0.61	-0.01 nanograms per millilitre (ng/mL) Standard Deviation 0.52
Mean Change From Baseline in Total Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 24	0.00 nanograms per millilitre (ng/mL) Standard Deviation 0.68	0.11 nanograms per millilitre (ng/mL) Standard Deviation 0.77	0.21 nanograms per millilitre (ng/mL) Standard Deviation 0.52	0.24 nanograms per millilitre (ng/mL) Standard Deviation 0.57	0.04 nanograms per millilitre (ng/mL) Standard Deviation 0.44
Mean Change From Baseline in Total Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 36	0.08 nanograms per millilitre (ng/mL) Standard Deviation 0.42	0.05 nanograms per millilitre (ng/mL) Standard Deviation 0.42	0.25 nanograms per millilitre (ng/mL) Standard Deviation 0.39	0.33 nanograms per millilitre (ng/mL) Standard Deviation 0.89	0.05 nanograms per millilitre (ng/mL) Standard Deviation 0.56

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 12, 13, 16, 24, and 36

Population: Analysis included all randomized participants who had received study treatment and had evaluable pharmacodynamic samples at a given timepoint.

Free Ang-2 concentrations were determined in plasma samples using an appropriate assay method. The lower limit of quantification (LLOQ) of the assay was 0.9 nanograms per millilitre (ng/mL). Plasma free Ang-2 concentrations below the limit of quantification were imputed as LLOQ divided by 2.

Outcome measures

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=68 Participants Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 Participants Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 Participants Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 Participants Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 Participants Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Mean Change From Baseline in Free Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Baseline (BL) - Value at Visit	2.19 nanograms per millilitre (ng/mL) Standard Deviation 1.38	1.81 nanograms per millilitre (ng/mL) Standard Deviation 0.73	1.88 nanograms per millilitre (ng/mL) Standard Deviation 0.98	1.73 nanograms per millilitre (ng/mL) Standard Deviation 0.75	1.95 nanograms per millilitre (ng/mL) Standard Deviation 1.12
Mean Change From Baseline in Free Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 4	0.00 nanograms per millilitre (ng/mL) Standard Deviation 0.57	0.14 nanograms per millilitre (ng/mL) Standard Deviation 0.37	-0.05 nanograms per millilitre (ng/mL) Standard Deviation 0.46	0.15 nanograms per millilitre (ng/mL) Standard Deviation 0.62	-0.07 nanograms per millilitre (ng/mL) Standard Deviation 0.55
Mean Change From Baseline in Free Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 12	0.23 nanograms per millilitre (ng/mL) Standard Deviation 1.12	0.20 nanograms per millilitre (ng/mL) Standard Deviation 0.57	0.12 nanograms per millilitre (ng/mL) Standard Deviation 0.52	0.21 nanograms per millilitre (ng/mL) Standard Deviation 0.75	-0.01 nanograms per millilitre (ng/mL) Standard Deviation 0.59
Mean Change From Baseline in Free Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 13	0.03 nanograms per millilitre (ng/mL) Standard Deviation 0.92	0.23 nanograms per millilitre (ng/mL) Standard Deviation 0.69	0.81 nanograms per millilitre (ng/mL) Standard Deviation 1.11	0.55 nanograms per millilitre (ng/mL) Standard Deviation 0.75	0.32 nanograms per millilitre (ng/mL) Standard Deviation 0.93
Mean Change From Baseline in Free Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 16	0.06 nanograms per millilitre (ng/mL) Standard Deviation 0.77	0.17 nanograms per millilitre (ng/mL) Standard Deviation 0.95	0.15 nanograms per millilitre (ng/mL) Standard Deviation 0.62	0.22 nanograms per millilitre (ng/mL) Standard Deviation 0.67	-0.11 nanograms per millilitre (ng/mL) Standard Deviation 0.65
Mean Change From Baseline in Free Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 24	0.18 nanograms per millilitre (ng/mL) Standard Deviation 0.90	0.20 nanograms per millilitre (ng/mL) Standard Deviation 0.93	0.25 nanograms per millilitre (ng/mL) Standard Deviation 0.49	0.39 nanograms per millilitre (ng/mL) Standard Deviation 0.58	0.13 nanograms per millilitre (ng/mL) Standard Deviation 0.59
Mean Change From Baseline in Free Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants Change from BL at Week 36	0.16 nanograms per millilitre (ng/mL) Standard Deviation 0.74	0.25 nanograms per millilitre (ng/mL) Standard Deviation 0.65	0.28 nanograms per millilitre (ng/mL) Standard Deviation 0.63	0.51 nanograms per millilitre (ng/mL) Standard Deviation 1.30	0.06 nanograms per millilitre (ng/mL) Standard Deviation 0.66

Adverse Events

Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)

Serious events: 9 serious events

Other events: 39 other events

Deaths: 0 deaths

Arm B: Faricimab, 1.5 mg Q4W

Serious events: 11 serious events

Other events: 31 other events

Deaths: 0 deaths

Arm C: Faricimab, 6 mg Q4W

Serious events: 7 serious events

Other events: 24 other events

Deaths: 0 deaths

Arm D: Faricimab, 6 mg Every 4-8 Weeks

Serious events: 5 serious events

Other events: 32 other events

Deaths: 0 deaths

Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W

Serious events: 8 serious events

Other events: 40 other events

Deaths: 1 deaths

Serious adverse events

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 participants at risk Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 participants at risk Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 participants at risk Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 participants at risk Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 participants at risk Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Cardiac disorders Acute myocardial infarction	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Cardiac disorders Atrial fibrillation	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Cardiac disorders Atrial flutter	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Cardiac disorders Cardiac arrest	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Cardiac disorders Cardiac disorder	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Cardiac disorders Cardio-respiratory arrest	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Cardiac disorders Coronary artery disease	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Cardiac disorders Degenerative mitral valve disease	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Cardiac disorders Pericardial effusion	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Glaucoma	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Keratic Precipitates	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Macular hole	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Neovascular age-related macular degeneration	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Retinal haemorrhage	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Visual acuity reduced	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Gastrointestinal disorders Constipation	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
General disorders Chest pain	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Hepatobiliary disorders Cholelithiasis	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Cystitis	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Endophthalmitis	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Escherichia urinary tract infection	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Herpes zoster	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Infectious colitis	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Pneumonia	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Injury, poisoning and procedural complications Lower limb fracture	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Injury, poisoning and procedural complications Road traffic accident	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Investigations Arteriogram coronary	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Investigations Blood potassium increased	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Metabolism and nutrition disorders Dehydration	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer recurrent	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive ductal breast carcinoma	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive lobular breast carcinoma	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Spindle cell sarcoma	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Nervous system disorders Cerebrovascular accident	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Nervous system disorders Transient ischaemic attack	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Renal and urinary disorders Nephrolithiasis	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Renal and urinary disorders Renal failure	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Reproductive system and breast disorders Postmenopausal haemorrhage	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Surgical and medical procedures Pulmonary resection	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Vascular disorders Hypertension	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Vascular disorders Shock	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

Other adverse events

Measure	Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) n=67 participants at risk Participants received ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) once every 4 weeks (Q4W) up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm B: Faricimab, 1.5 mg Q4W n=46 participants at risk Participants received faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit took place at Week 36.	Arm C: Faricimab, 6 mg Q4W n=39 participants at risk Participants received faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit took place at Week 36.	Arm D: Faricimab, 6 mg Every 4-8 Weeks n=46 participants at risk Participants received faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit took place at Week 36.	Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W n=64 participants at risk Participants received ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit took place at Week 36.
Eye disorders Anterior chamber cell	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	5.1% 2/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Blepharitis	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	5.1% 2/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Cataract	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	5.1% 2/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Conjunctival haemorrhage	20.9% 14/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	8.7% 4/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	15.4% 6/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	13.0% 6/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	9.4% 6/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Dry age-related macular degeneration	6.0% 4/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Eye irritation	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	10.3% 4/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	8.7% 4/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Eye pain	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	8.7% 4/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	5.1% 2/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	10.9% 5/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.7% 3/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Lacrimation increased	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	6.5% 3/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Neovascular age-related macular degeneration	9.0% 6/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	8.7% 4/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	7.7% 3/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	7.8% 5/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Posterior capsule opacification	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	7.7% 3/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Punctate keratitis	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	7.8% 5/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Retinal pigment epithelial tear	4.5% 3/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	5.1% 2/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Vision blurred	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	7.7% 3/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Vitreous detachment	4.5% 3/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	10.9% 5/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	7.7% 3/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	10.9% 5/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	6.2% 4/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Vitreous floaters	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	6.5% 3/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	10.3% 4/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	6.5% 3/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Gastrointestinal disorders Constipation	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	5.1% 2/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Bronchitis	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	5.1% 2/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Influenza	4.5% 3/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	6.5% 3/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Nasopharyngitis	13.4% 9/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	8.7% 4/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	7.8% 5/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Pneumonia	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	6.5% 3/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Urinary tract infection	9.0% 6/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	23.9% 11/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	5.1% 2/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.7% 3/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Injury, poisoning and procedural complications Fall	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	6.5% 3/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.7% 3/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Investigations Intraocular pressure increased	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	6.5% 3/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Investigations Weight decreased	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	5.1% 2/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Investigations Weight increased	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	5.1% 2/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Psychiatric disorders Anxiety	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	6.2% 4/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Psychiatric disorders Insomnia	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	5.1% 2/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Vascular disorders Hypertension	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	6.5% 3/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.7% 3/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Ear and labyrinth disorders Vertigo	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Anterior chamber flare	4.5% 3/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Dry eye	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Eye disorders Visual acuity reduced	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Gastrointestinal disorders Diarrhoea	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
General disorders Pyrexia	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
General disorders Sensation of foreign body	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Injury, poisoning and procedural complications Corneal abrasion	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Cystitis	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.7% 3/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Gastroenteritis viral	4.5% 3/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Laryngitis	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Sinusitis	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Tooth abscess	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Infections and infestations Upper respiratory tract infection	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Investigations Red blood cell sedimentation rate increased	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Metabolism and nutrition disorders Dehydration	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Metabolism and nutrition disorders Gout	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Musculoskeletal and connective tissue disorders Back pain	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.7% 3/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Musculoskeletal and connective tissue disorders Joint swelling	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.6% 1/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Musculoskeletal and connective tissue disorders Musculoskeletal stiffness	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Musculoskeletal and connective tissue disorders Pain in extremity	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	1.6% 1/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Nervous system disorders Dizziness	1.5% 1/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Nervous system disorders Headache	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Nervous system disorders Migraine	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Psychiatric disorders Depression	0.00% 0/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Respiratory, thoracic and mediastinal disorders Sinus congestion	3.0% 2/67 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	2.2% 1/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	0.00% 0/39 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	4.3% 2/46 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)	3.1% 2/64 • From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

Additional Information

Medical Communications

Hoffmann-La Roche

Phone: 800-821-8590

Email: genentech@druginfo.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
• Publication restrictions are in place

Restriction type: OTHER